Attractive Targeted Sugar Baits for malaria control in western Kenya (ATSB-Kenya) – Effect of ATSBs on epidemiologic and entomologic indicators: a Phase III, open-label, cluster-randomised, controlled trial

Caroline Ogwang[1,2]*, Aaron M Samuels[3,4], Daniel P McDermott[5], Alice Kamau[1,2], Maia Lesosky [2,#a], Kizito Obiet[1], Julia M Janssen[3], Wycliffe Odongo[3], John E Gimnig[3], Julie R Gutman[3], Jonathan S Schultz[3,4], Oliver Towett[1], Brian Seda[1], Mercy Chepkirui[1], Margaret Muchoki[1], Seline Omondi[1], Jackline Kosgei[1], Brian Polo[1], Frank Aduwo[1], Kephas Otieno[1], Martin J Donnelly[5], Simon Kariuki[1], Eric Ochomo[1,5], Feiko ter Kuile[1,2]¶ Sarah G Staedke[1,2,5]¶

1   KEMRI Centre for Global Health Research, Kisumu, Kenya

2   Department of Clinical Sciences, Liverpool School of Tropical Medicine, UK

3   Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

4   Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Kisumu, Kenya

5   Department of Vector Biology, Liverpool School of Tropical Medicine, UK

#a   Current Address: National Heart and Lung Institute, Imperial College London, UK

* Corresponding author; E-mail: caroline.ogwang@lstmed.ac.uk (CO)

¶These authors contributed equally to this work.

1 Abstract

Attractive targeted sugar baits (ATSBs) are a novel malaria control tool designed to target

mosquitoes outdoors. We conducted a cluster-randomised trial to evaluate the impact of ATSBs on

malaria indicators in Kenya. Seventy clusters (≥100 households/cluster) in Siaya county were

randomly assigned (1:1) to intervention or control. Pyrethroid-only long-lasting insecticidal nets

were distributed to all clusters, aiming for universal coverage. Two ATSBs containing dinotefuran

were hung outside household structures in intervention clusters. ATSBs were monitored every two

months and replaced every six months over two years. Three consecutive cohorts of randomly

selected children (1-<15 years) were enrolled, aiming to accrue 1,260 person-years over two years of

follow-up. Incidence of clinical malaria (fever with a positive malaria test) was the primary outcome.

A multilevel Poisson regression model was applied, with clusters as a random intercept and study

arm as a fixed effect. Secondary outcomes were malaria prevalence in community residents (≥1

month), and parity of mosquitos captured through human landing catches. In March 2022, ATSBs

were delivered to 33,180 of 33,419 (99.3%) household structures in intervention clusters. Overall,

268,268 ATSBs were deployed over two years. Of 2,962 cohort children enrolled

(intervention=1,497; control=1,465), 2,869 (96.9%) were included in the primary analysis

(intervention=1,461; control=1,408), contributing 1,445 person-years of follow-up. Malaria incidence

was 1.32 episodes per person-years in the intervention arm versus 1.20 in the control (unadjusted

incidence rate ratio 1.11; 95% CI: 0.75-1.65; p=0.598). Of 7,488 community residents surveyed

(intervention=3,760; control=3,728), 1,474 (39.2%) intervention and 1,461 (39.2%) control

participants tested positive for malaria (unadjusted odds ratio [OR] 0.98; 95% CI: 0.60-1.59; p=0.93).

Of 6,457 female anopheles mosquitoes collected (intervention=4,058; control=2,399), 3,579 (88.2%)

intervention and 1,973 (82.2%) control mosquitoes were parous (OR 1.34; 95% CI: 0.91-1.99;

p=0.14). In Kenya, we found no evidence that ATSBs reduced clinical malaria incidence, malaria

prevalence, or vector parity.

Trial registration

Clinicaltrials.gov (NCT05219565), 22 January 2022; https://clinicaltrials.gov/study/NCT05219565

Keywords

malaria, attractive targeted sugar bait (ATSB), vector control, cluster-randomised trial, Kenya

Introduction

Between 2000 to 2015, the prevalence and incidence of *Plasmodium falciparum* in Africa fell by 50% and 40%, respectively, primarily due to the scale-up of long-lasting insecticidal nets (LLINs), indoor residual spraying (IRS) and treatment with artemisinin-based combination therapies (ACTs) [1]. Since 2015, however, progress on malaria control has plateaued [2]. Malaria control efforts were hindered by the COVID-19 pandemic, but widespread resistance to pyrethroid insecticides, climate change, fluctuations in vector species, changes in mosquito behaviours, and resistance to artemisinin and partner drugs are other threats [2-6]. In Kenya, malaria burden remains high in the western, lake-endemic region, despite distribution of LLINs and targeted IRS [7].

LLINs are the most widely used vector control tool, supplemented by IRS [2]. Both tools target mosquito vectors that feed and rest indoors. However, vector behaviours are shifting, with increased biting outdoors and later in the morning hours, when individuals are less likely to be protected by LLINs [5, 8]. Novel tools, such as attractive targeted sugar baits (ATSBs) that target mosquitoes outdoors are needed to complement other control interventions deployed indoors. ATSBs are A4-sized panels containing fruit syrup laced with an insecticide, which exploits the sugar-feeding behaviour of mosquitoes [9]. ATSBs attract mosquitoes, luring them to feed and ingest the insecticide, which kills the mosquitoes.

In 2017, an initial entomological field trial of ATSBs was conducted in Mali, which found ATSBs were associated with significant reductions in vector density, sporozoite rate, and entomologic inoculation rate (EIR) associated with ATSBs [10]. Subsequent modelling studies suggested that ATSBs could reduce malaria incidence and parasite prevalence by over 30% annually [11]. Given these promising results, results from Zambia indicating that *Anopheles funestus* and *An. gambiae* fed readily from the ATSB stations [12], and the predicted impact of ATSBs on malaria transmission [11, 13], large-scale, Phase III cluster-randomised, controlled trials were launched in 2021 to further evaluate the

59 epidemiological and entomological impact of ATSBs in Kenya, Mali and Zambia [14]. Here, we

60 present the results of the Kenyan trial.

Methods

63 The protocol and statistical analysis plan for the multi-country ATSB trial have been published

64 previously [14, 15]. A description of cohort recruitment (Fig1), and the characteristics of children and

65 households at enrolment, have also been published [16].

Study setting

The trial was conducted in Alego-Usonga and Rarieda sub-counties in Siaya County, western Kenya

(Fig2), in the region of the Health and Demographic Surveillance System (HDSS) established by the

Kenya Medical Research Institute and the US Centers of Disease Control and Prevention, which has

been described in detail [17, 18]. Briefly, malaria transmission is perennial in this area with

prevalence peaking between May-June and November-December, following the long and short

rains. Malaria prevalence by microscopy in the study area was 36.8% in 2013, and was highest in

children aged 5-14 years (57.9%) [19]. The primary malaria vectors are *An. funestus* and *An.*

arabiensis [5, 20]. Artemether-lumefantrine (AL) has been used as the first-line therapy for case

management since 2006, LLIN mass campaigns are conducted every 3-5 years (2014, 2017, 2021),

and IRS is not implemented in this area [21].

Assignment of interventions

Following a census conducted from December 2020 to March 2021, we established 80 clusters by

purposely grouping 1-3 adjacent villages to create a cluster of sufficient population size. To minimise

contamination, clusters were divided into core and buffer areas, with core areas 300-600 meters

from the perimeter, and 600-1,200 meters between cores of contiguous clusters. We aimed for a

core population of 100-400 households. Prior to randomisation, malaria incidence, prevalence, and

contextual data were collected in the 80 clusters. Subsequently, 10 clusters with the fewest children

aged 1-<15 years were removed, to limit resampling of individuals. Thus, 70 of the original 80

clusters were included in the trial.

Clusters were assigned to study arms using restricted randomisation to minimise imbalances,

considering key baseline characteristics (malaria incidence, bednet use, RTS,S/AS01 vaccination

implemented within the cluster, housing density, study clinic location, altitude, and entomological

indicators), as described previously [14, 15]. A list of 100,000 possible allocation sequences was

generated by a study team member not involved in trial implementation and checked against

balance criteria. Any sequences that failed to balance these criteria were dropped. The remaining

sequences were assessed for validity, and one was chosen randomly. Assignment to intervention or

control was determined by a coin toss. The 70 clusters (32 in Alego Usonga and 38 in Rarieda) were

randomised in a 1:1 ratio, 35 to the intervention arm and 35 to control. Allocation of study arms was

not blinded to the investigators, field team or participants. However, laboratory technicians were

blinded.

Intervention delivery

ATSB® Sarabi Bait Station (version 1.2, Westham Co., Hod-Hasharon, Israel) containing dinotefuran, a

neonicotinoid insecticide, were deployed to consenting households in the 35 intervention clusters, in

both core and buffer areas, beginning in March 2022 (see timeline in Fig3). Two ATSB stations were

hung approximately 1.8 meters above the ground on the exterior walls of all eligible household

structures (those with a complete roof, walls $\geq$1.8 m high, and at least three complete exterior

walls). The study team visited households to monitor ATSBs every two months. ATSBs that were

missing or damaged were replaced, and all ATSB stations were replaced every six months. Four

rounds of ATSBs were deployed over two years. All ATSBs were removed from the field in April 2024;

used ATSBs were incinerated. Pyrethroid-only LLINs were distributed in Siaya county by the Kenyan

Ministry of Health in June 2021, aiming to achieve universal coverage (one LLIN for every two

household residents). During the trial, the study team delivered supplemental pyrethroid-only LLINs

to all clusters in October 2022 to households with inadequate LLIN coverage (less than one LLIN per

two residents).

Cohort study

Three consecutive cohorts of children aged 1-<15 years were enrolled in March-April 2022,

September-October 2022, and March-April 2023. The first two cohorts were followed for up to 6.5

months, while the third cohort was followed for up to 12.5 months. In total, the cohorts were

followed from March 2022 to April 2024.

A list of randomly selected children aged 1-<15 years was generated for recruitment from the

baseline census list for each cluster. A new list was generated for each cohort. Children on the

recruitment list were invited for a screening appointment at one of nine dedicated study clinics

staffed by study clinicians and community interviewers. Children were enrolled in the cohort study if

they met the following selection criteria: (1) age 1 to < 15 years; (2) resident of the household (over

the previous four months, and intending to stay for an additional 6-12 months); (3) provision of

written informed consent by their parent or guardian; (4) provision of assent by children aged 13-14

years; (5) no evidence of pregnancy; (6) not taking cotrimoxazole prophylaxis; (7) no known sickle

cell disease; (8) no contraindication to AL; and (9) not currently enrolled in another interventional

study or enrolled in the previous ATSB cohort.

At enrolment, information was collected on demographics, clinical history, and self-reported LLIN

use the previous night. Children were asked about history of fever within the past 48 hours, and

axillary temperature was measured. A finger-prick blood sample was collected for rapid diagnostic

test (RDT) for malaria (First Response® Malaria Ag pLDH/HRP2 Combo Card kit) and storage on filter

paper at -80°C for future molecular studies. All participants were treated with AL, regardless of the

RDT result. Two weeks after enrolment, participants were asked to return to the clinic to assess

parasite clearance. Participants testing positive at the clearance visit were treated with either AL or

dihydroartemisinin-piperaquine (DP), according to Ministry of Health guidelines. A household survey

was conducted soon after enrolment to collect information on household characteristics, house

construction, indicators of socioeconomic status, and LLIN ownership.

Cohort participants were encouraged to seek care at study clinics and were scheduled for routine

clinic visits every 4 weeks. At each monthly visit, information was collected on any recent illness,

care-seeking, LLIN use, and travel history. A finger-prick capillary blood sample was collected for

storage on filter paper. If the cohort participant missed a scheduled visit, their parent or guardian

was called. If we failed to reach them after three attempts, a field worker was sent to their house. If

a participant sought care outside of the study, information on symptoms, malaria testing, and

antimalarial treatment were recorded. If a child was febrile (axillary temperature $\geq 37.5°C$ or history

of fever in the previous 48 hours) at any clinic visit, a RDT was performed. If the child had been

treated for malaria within the past 5 weeks, a blood smear was prepared for microscopy, instead of

an RDT. If the RDT or blood smear was positive, the child was treated according to the Kenya

Ministry of Health guidelines with AL or DP. Children with severe malaria were referred to the

nearest hospital for treatment with parenteral artesunate. Cohort participants were excluded after

enrolment if they withdrew consent, moved out of the study area, or met any of the exclusion

criteria for cohort participation.

Continuous malaria indicator surveys (cMIS)

A cMIS survey measured malaria prevalence cross-sectionally in community residents throughout

the year from April 2022 to February 2024. Households from each cluster were randomly selected

162 from a census list and were visited once. Written informed consent and assent (for children aged 13-

163 17 years) were sought for all household residents (aged $\geq$1 month) who were present on the day of

164 the survey. Information on demographics, housing characteristics, and LLIN ownership and use was

165 obtained from the head of household, or their designee. A finger-prick blood sample was collected

166 from each consenting participant for an RDT. Participants who tested positive were treated with AL.

168 **Entomology surveys**

169 Mosquito collections using human landing catches (HLC) and CDC ultraviolet light traps (UVLT) were

170 conducted monthly from April 2022 to March 2024 in 16 randomly selected clusters using a stratified

171 approach to ensure study arm assignments were balanced across the area. Trained community

172 members consented to participate as mosquito collectors. Ten households enrolled in the cohort

173 study were randomly chosen per cluster to participate in the HLCs. Initially, HLC collections were

174 conducted indoors and outdoors from 6:00 PM to 6:00 AM. In October 2022, the sampling period

175 was extended to 11:00 AM to capture late morning biting. UVLT collections were paired with the

176 HLCs and conducted in the same 16 clusters, but in ten different households located within 50

177 meters of each HLC household. The timing of UVLT collections mirrored the HLCs. Seven cross-

178 sectional UVLT collections were also done in the 70 clusters, in February 2022 (baseline), May and

179 November 2022, May, July and November 2023, and February 2024 (Fig3). At each point, ten

180 households were randomly sampled in the remaining 54 clusters, resulting in comprehensive data

181 from all 70 clusters.

183 **Laboratory procedures**

184 For microscopy, thick and thin blood smears were prepared on the same slide by study clinicians and

185 were transported to the laboratory in Siaya County. Details on slide preparation and microscopy

186 procedures are included in the supplemental file. All slides were read by a second microscopist, and

a third independent reviewer settled any discrepant readings. Mosquitoes collected using HLCs and

UVLTs were transported to the laboratory for morphological identification. All undamaged, unfed

female *Anopheles* spp. mosquitoes captured alive during HLCs were dissected to assess parity by the

ovary tracheation method [22].

Sample size calculations

Full details of the sample size calculations are provided in the trial master protocol and statistical

analysis plan [14, 15]. A sample size of 1,260 person-years (630 person-years per arm) was required

to detect a ≥30% reduction in the incidence of clinical malaria among children aged 1-<15 years

(from 845 per 1,000 person-years in the control arm to 592 in the intervention arm over two years),

assuming a coefficient of variation of 0.4, two-sided alpha of 0.049, 80% power, and an anticipated

20% loss of person-time due to loss to follow up or consent withdrawal. For cMIS, a sample size of

4,200 participants annually (60 per cluster) was required to detect a 30% reduction in RDT-

confirmed malaria prevalence, from 29.0% to 20.3%, assuming an intra-cluster correlation

coefficient (ICC) of 0.05, 80% power, a two-sided alpha of 0.05, and a 20% non-response rate,

allowing for analysis within each 6-month sampling period. For vector parity, simulations (n=1,000)

accounting for variation between clusters, household, months and monthly catch were conducted

[23], assuming a two-sided alpha of 0.05, power of 80%, ICC of 0.04, expected female *Anopheles* per

trap night of 2.5, and 16 clusters (8 per arm). To detect a 9%-point reduction, from 50% parity in the

control arm, we estimated that ten entomological collections per cluster per month were required.

Outcome measures

Incidence of malaria (clinical malaria cases per person-year) in children aged 1-<15 years was the

primary outcome, defined as fever (axillary temperature of ≥37.5°C or history of fever within the

past 48 hours) plus a positive malaria test (RDT or microscopy). Malaria cases diagnosed within 14

days of AL treatment, or 28 days of DP treatment, were not counted as incident cases. To account

for the post-treatment prophylactic effect of AL and DP, the at-risk person-time was adjusted by

subtracting 14 days for each AL treatment, and 28 days for each DP treatment. Temporary absences

from the study area that did not interfere with monthly clinic visits were not considered to reduce

individual exposure time. However, absences >35 days were excluded from exposure time.

Secondary outcomes included (i) malaria prevalence: proportion of participants aged ≥ 1 month

testing positive by RDT; (ii) parity: proportion of dissected mosquitoes that were parous; (iii) vector

density (the number of female *Anopheles* collected per household). All entomological outcomes

were calculated for all *Anopheles* spp. collected and disaggregated by species complexes based on

morphological identification.

Analytical approach

All analyses were done using the intention-to-treat population. For the primary outcome, a multi-

level variance components model within a generalised linear framework with a Poisson likelihood

and a log link function was used. A random intercept was included for cluster, and study arm was

included as a fixed effect. We examined the distributional assumption that the mean and variance of

the outcome were similar after accounting for cluster effects. Adjusted analyses including pre-

specified covariates (sub-county, age, gender, housing type, baseline cluster-level malaria incidence

and adequate bednet coverage, defined as one net per two residents) were conducted [15]. Other

factors considered in the restricted randomisation were not included in the adjusted (or unadjusted)

analyses. Household structures were classified as 'improved' (finished walls and roofs, and closed

eaves) or 'traditional' (all other construction). Subgroup analyses by factors specified a priori (age,

gender, baseline parasite prevalence, housing type) were also conducted by including the subgroup

variable and an interaction term with study arm in an adjusted analysis. If the *p*-value of the

interaction terms was <0.05, separate effect estimates and confidence intervals for each sub-group

were presented.

Malaria prevalence was analysed using a multi-level variance components model within a

generalised linear framework, with a Bernoulli likelihood and a logit link function. A random

intercept was included for each study cluster, and the study arm was treated as a fixed effect.

Adjusted analyses included pre-specified covariates (region, age, gender, bednet use) [15]. Vector

parity and density were analysed using individual-level data through generalised linear mixed

models. Both unadjusted and adjusted analyses were conducted, with a random effect for clusters

included in the models. For the unadjusted analysis of parity, a Bernoulli likelihood was used with a

logit link function and a fixed effect for the study arm. The adjusted analysis included fixed effects

for collection location (indoors vs. outdoors), time since intervention, and calendar month for

seasonality. For density, a negative binomial distribution was used to account for overdispersion.

The unadjusted analysis included a fixed effect for the study arm, while the adjusted model

considered collection location, time since intervention, and calendar month. Analyses were

completed using R version 4.4.1.

Research ethics approval

The trial was approved by the Kenya Medical Research Institute Scientific and Ethics Review Unit

(KEMRI SERU: 4189), Institutional Review Board of the US Centers for Disease Control and

Prevention (IRB: 00008118), and the Liverpool School of Tropical Medicine Research Ethics

Committee (LSTM REC: 21-027). A license for the trial was also granted by the National Commission

for Science, Technology, and Innovation (NACOSTI) in Kenya.

Role of the funding source

The ATSB study multi-country consortium, including researchers and technical advisors from IVCC

(the funder), designed the trial and aligned it across the three countries [14, 15]. IVCC had no role in

data collection, analysis, or interpretation, or writing of the report. All authors had full access to the

study data and had final responsibility for the decision to submit for publication.

Results

Cohort recruitment

Of 4,509 children on the cohort recruitment lists (Fig1), 804 could not be contacted (399

intervention; 405 control), and 3,705 children were screened (1,858 control; 1,847 intervention). Of

these, 523 children were not eligible (250 intervention; 273 control), and 220 did not consent (111

intervention; 109 control). Reasons for exclusion are detailed in Table S1. Overall, 2,962 children

were enrolled (1,497 intervention; 1,465 control), including 1,000 in cohort-1, 969 in cohort-2, and

993 in cohort-3.

Characteristics of participants and households

Characteristics of cohort participants and households were similar in both arms (Table 1). The mean

cluster-level proportion of children aged <5 years, 5-9 years, and 10-<15 years was 26.5% (SD 7.4%),

34.2% (SD 7.8%), and 39.3% (SD 8.9%), respectively. The median cluster-level prevalence of positive

RDTs at enrolment was 45.7% (IQR: 28.6%, 67.9%) in the intervention arm and 48.7% (IQR: 24.3%,

61.8%) in the control. We surveyed 2,644 households of 2,886 (97%) participants. The cluster-level

household size and socio-economic index were evenly distributed across both study arms. Most

houses were classified as traditional construction, primarily due to open eaves. Nearly all households

owned at least one bed net; however, the mean cluster-level proportion of households that owned

at least one net for every two residents was only 51.4% (SD 9.7%).

Table 1. Cluster-level characteristics of cohort participants & households (stratified by study arm)

Variable	Characteristic	Cohort study	
		Control arm	Intervention arm
Number of clusters		35	35
Number of cohort participants enrolled		1,465	1,497
Female gender, mean (SD) [a]		47.1% (7.5%)	48.2% (7.2%)
Age categories, mean (SD) [a]	— 1 to < 5 years	27.5% (7.4%)	25.4% (7.4%)
	— 5 to 9 years	32.5% (7.1%)	35.9% (8.2%)
	— 10 to < 15 years	40.0% (8.0%)	38.6% (9.8%)
RDT positive, median (IQR) a		48.7% (24.3%, 61.8%)	45.7% (28.6%, 67.9%)
Number of households surveyed		1,311	1,333
Household size by cluster, mean (SD) [a]	— [1 - 4] residents	26.4% (7.3%)	24.7% (7.7%)
	— [5 - 7] residents	54.2% (9.0%)	56.1% (10.0%)
	— 8+ residents	17.8% (10.2%)	17.1% (9.5%)
Socioeconomic index in terciles, mean (SD) [a]	— Poorest	34.6% (10.7%)	31.3% (10.5%)
	— Poor	31.5% (8.3%)	34.3% (8.8%)
	— Least poor	33.9% (11.2%)	34.4% (11.2%)
Household construction, mean (SD) [a,b]	— Traditional	92.5% (5.0%)	92.2% (4.9%)
	— Modern	7.5% (5.0%)	7.8% (4.9%)
Net ownership, mean (SD) [a]	Households with at least one net	98.4% (2.4%)	98.8% (2.4%)
Adequate net coverage, mean (SD) [a]	Households with 1 net for every 2 residents	52.0% (9.7%)	50.8% (9.8%)

[a] *Proportions at the level of each cluster*

[b] *Houses were classified as 'modern' (synthetic walls and roofs, eaves closed or absent) or 'traditional' (all other construction)*

ATSB delivery

A total of 268,268 ATSBs were deployed between March 2022 and April 2024. Of the 33,419

household structures deemed eligible for ATSBs in March 2022, 183 did not consent, and another 56

did not receive ATSBs. Thus, 66,360 ATSBs were deployed to 33,180 (99.3%) structures. The mean

cluster-level coverage of ATSBs was 98.7% (range 96-100%) for eligible structures. In September

2022, March 2023, and September 2023, 66,868, 67,704, 67,336 ATSBs were deployed, respectively.

New structures were mapped and consented at each deployment round. Overall, during the 2-

monthly monitoring visits, 12,427 (4.6%) stations were missing (not present at the time of the

monitoring visit), and 42,297 (15.8%) met criteria for replacement, primarily due to mould, sugar

leakage, or damage, and were replaced with new ATSBs. All stations were replaced at the 6-month

mark. Further details on ATSB density and coverage will be published separately.

Cohort follow-up

Of the 2,962 children enrolled, 2,702 (91.2%) completed the 6th follow-up visit (1,375 intervention;

1,327 control). In cohort-3, 876 (88.2%) of 993 children completed the 12th follow-up visit (448

intervention; 428 control). Overall, 2,967 routine and sick visits (1,525 intervention; 1,442 control)

were associated with fever (elevated temperature $\geq$ 37.5^{o}C or history of fever in the past 48h). In the

intervention arm, 937 (71.5%) of 1,310 children tested with an RDT, and 131 (59.6%) of 220 children

tested by microscopy, were positive. In the control arm, 821 (66.4%) of 1,236 children tested with an

RDT, and 110 (49.8%) of 221 children tested by microscopy, were positive. Overall, 2,869 (96.9%)

participants (1,461 intervention, 1,408 control) were included in the primary endpoint analysis

(Fig1). Children were excluded if they missed the clearance visit, lacked a microscopy result at the

clearance visit (26 intervention; 37 control), or did not accrue eligible person-time after clearance (9

intervention; 18 control).

Impact on primary outcome: clinical malaria incidence

We captured 1,829 incident malaria cases over 1,445 person-years of follow-up. Malaria incidence

was 1.32 episodes per person-years in the intervention versus 1.20 in the control arm (Table 2).

There was no evidence of a difference in malaria incidence between the intervention and control

group in the unadjusted analysis (incidence rate ratio [IRR] 1.11; 95% CI: 0.75-1.65; p=0.598) or in

the multivariable analysis. The median cluster-level incidence of malaria overall was 1.275 cases per

person-year (range 0.04 to 4.59 cases per person-year). The coefficient of variation for malaria

incidence in the trial was 0.75. Subgroup analysis suggested that the effect of ATSBs varied by age (1-

<5 years: adjusted IRR 1.22 [95% CI: 0.84-1.77]; 5-<15 years: adjusted IRR 1.09 [95% CI: 0.77-1.53], p-

value for study arm x age group interaction=0.041) (Table 2). There were no sub-group differences

for other pre-specified factors. Overall, 18 serious adverse events (9 intervention; 9 control) were

reported; all were considered unrelated to the ATSB intervention (Table S2).

329 **Table 2. Malaria incidence (primary outcome)**

Study arm	Number of children	Episodes of malaria	Person years of observation at risk	Malaria Incidence	Unadjusted		Adjusted*	
					IRR (95% CI)	P value	IRR (95% CI)	P value
Overall								
Control	1408	857	711.64	1.20	Reference		Reference	
Intervention (ATSB)	1461	972	733.61	1.32	1.11 (0.75, 1.65)	0.598	1.10 (0.79, 1.52)	0.585
Age 1 to <5 years †								
Control	379	238	186.05	1.28	Reference		Reference	
Intervention (ATSB)	378	295	192.72	1.53	1.24 (0.76, 2.04)	0.565	1.22 (0.84, 1.77)	0.308
Age 5 to <15 years †								
Control	1029	619	525.59	1.18	Reference		Reference	
Intervention (ATSB)	1083	677	540.89	1.25	1.07 (0.74, 1.55)	0.728	1.09 (0.77, 1.53)	0.630

Adjusted for participant age, sex, adequate bednet coverage within household, housing, region, and baseline cluster-level malaria incidence (from baseline cohort)

† P-value = 0.041 for study arm x age category effect in primary outcome model fit with interaction term: ~ study arm + age category + study arm x age category, effect estimate for
interaction term 0.81 (0.66 - 0.99) (RR scale)

Impact on secondary outcomes: malaria prevalence

In the cMIS survey, 7,488 community residents (3,760 intervention; 3,728 control) from 1,685

households (850 intervention; 835 control) were tested for malaria using RDTs (Table 3). Of these,

1,474 (39.2%) intervention and 1,461 (39.2%) control participants tested positive. There was no

difference in the odds of malaria infection between the two groups in the unadjusted analysis (odds

ratio [OR] 0.98; 95% CI: 0.60-1.59; p-value 0.93), or in the multivariable analysis (Table 3).

342 **Table 3. Secondary epidemiological and entomological outcomes**

Survey	Indicator	Study arm		Unadjusted			Adjusted	
			n/N (%)	OR (95% CI)	p-value	OR (95% CI)	p-value
Continuous malaria indicator survey	RDT positivity (all ages) *	Control	1461/3728 (39.19)	Ref		Ref	
		Intervention (ATSB)	1474/3760 (39.20)	0.98 (0.60–1.59)	0.93	0.97 (0.68–1.37)	0.85
Entomology surveillance	Parity (Female Anopheles spp.) †	Control	1973/2399 (82.2)	Ref		Ref	
		Intervention (ATSB)	3579/4058 (88.2)	1.34 (0.905–1.99)	0.14	1.30 (0.87–1.94)	0.201

Indicator	Study arm	Households sampled	Total Collected	Household Mean (SD)	Household Median (IQR)	Cluster Median (IQR)	IRR (95% CI)	p-value	IRR (95% CI)	p-value
Density by HLCs	Control	1925	10,846	5.63 (13.6)	0 (0 – 4)	2.06 (1.20–7.52)	Ref		Ref	
(Female *Anopheles spp.*)	Intervention	1924	28,840	15 (46)	0 (0 – 5)	0.913 (0.52–11.2)	0.954 (0.145–6.27)	0.96	0.985 (0.142–6.82)	0.99
Density by UVLTs	Control	1927	18,191	9.44 (22.1)	3 (0 – 9)	5.46 (3.93–10.8)	Ref		Ref	
(Female *Anopheles spp.*)	Intervention	1924	37,531	19.5 (52.7)	2 (0 – 14)	4.08 (1.96–22.5)	0.960 (0.257–3.59)	0.952	0.94 (0.244–3.63)	0.929
Density by UVLT CSS	Control	2103	22,797	10.8 (21.7)	3 (0 – 12)	7.15 (3.78–13.6)	Ref		Ref	
(Female *Anopheles spp.*)	Intervention	2104	29,792	14.2 (28.4)	3 (0 – 15)	5.58 (2.71–20.3)	1.02 (0.548–1.90)	0.952	0.954 (0.63–1.44)	0.822

343 *cMIS analysis adjusted for study arm (ATSB), region, sex, age in year of survey & bednet use (slept under net last night)*

344 *† Parity analysis includes fixed effects for collection location (indoors vs. outdoors), time since intervention and calendar month as a seasonality adjustment*

345 *‡ Adjusted analysis for density includes fixed effects for study arm (ATSB) + log(baseline anopheline species number) and random effects for cluster & round*

346

Impact on secondary outcomes: entomology indicators

Between April 2022 and March 2024, 6,457 female *Anopheles spp* were collected and evaluated for

parity (4,058 intervention; 2,399 control) (Table 3). Of these, 3,579 (88.2%) in the intervention arm

and 1,973 (82.2%) in the control arm were parous. There was no difference in the odds of parity

between the groups in the unadjusted analysis (OR 1.34; 95% CI: 0.905-1.99; p=0.14), or in the

multivariable analysis. Similarly, no evidence of difference in the density of female *Anopheles spp*

was found when using human landing catches or UV light traps in the unadjusted or adjusted

analyses. Species-specific results for *An. funestus and An. gambiae* were similar, with no significant

differences in parity or density between the intervention and control groups stratified by species or

collection strategy (Table S3). Detailed results of the entomology surveys will be published

separately.

Discussion

In this trial, we evaluated the impact of ATSBs on malaria indicators in western Kenya. Despite

promising results from a preliminary entomology study in Mali [10], epidemiological modelling

suggesting that ATSBs could substantially reduce malaria burden in similar settings [11], and a choice

experiment in semi-field enclosures in Kenya suggesting that ATSBs were more attractive to local

Anopheles mosquitoes than natural sugar sources [12], we found no evidence that ATSBs reduced

malaria incidence in children aged 1-<15 years, malaria prevalence in community residents of all

ages, or vector parity or density in western Kenya. Our results are consistent with the findings from

the partner trial in Zambia, which found no impact of ATSBs on clinical malaria incidence, parasite

prevalence or entomological indicators in a setting with seasonal malaria transmission [24, 25]. The

lack of ATSB effectiveness is likely attributable to multiple factors, including competing sugar sources

for vector feeding in Kenya [26, 27], uncertainty about optimal intervention coverage in this setting,

product design and limited interaction with the product by local vector populations [10, 28]. For

ATSBs to effectively control malaria, a sufficient proportion of the mosquito population must be

attracted to, subsequently feed on the insecticide-laced syrup in ATSB stations, and be killed, thus

reducing the vector population and ultimately malaria transmission. It is unclear where along this

pathway ATSBs failed in Kenya. However, the lack of entomological impact on vector density

suggests that ATSBs did not work in western Kenya, as they appeared to in the Mali trial [10].

Why were ATSBs not effective in Kenya? Did ATSBs fail to lure mosquitoes, perhaps due to

competition with other natural sugar sources? This seems plausible given the range and quantity of

natural sugar sources in the environment which could lead to insufficient coverage [29]. Did

mosquitoes fail to feed on the ATSBs, or did the insecticide fail to kill mosquitoes? This is possible,

although laboratory experiments suggest that the mosquitoes did feed on the devices, and those

that fed, died [30]. Or, was the proportion of mosquitoes affected by ATSBs insufficient to reduce

vector density, parity and transmission in our setting? This seems most likely. Inadequate density

and coverage of ATSB devices, the abundance of alternative food sources, or the sheer numbers of

mosquitoes in the area may have all contributed. Modelling studies on mosquito feeding behaviour

and the potential of ATSBs to control mosquito populations and *Plasmodium falciparum* malaria

prevalence were fitted to data from Mali [11, 13]. However, natural sugar sources are more

abundant in western Kenya than in Mali. The effectiveness of ATSBs may be context specific with

higher efficacy in more arid regions. Studies in Mali and Israel, sites with less natural sugar sources,

have demonstrated a strong entomological impact of ATSBs [10, 26, 31, 32]. However, in Zambia, the

Phase III cluster-randomised trial evaluating ATSBs found that while vector density was reduced (but

not significantly) by 35%, no difference was observed in parity, sporozoite rate or EIR [24], and

correspondingly no significant reductions in clinical malaria incidence or malaria prevalence were

observed [25]. Full results of the companion trial in Mali may shed more light on the efficacy of

ATSBs in different settings.

Our study had several limitations. First, we currently lack a specific density target for spatial

deployment of ATSBs, and it remains unclear how bait stations interact with environmental factors

such as vector larval site locations, natural sugar sources, housing construction and human

settlement patterns. Further research is needed to better understand the impact of intervention

density and coverage, to optimise their effectiveness in diverse malaria transmission settings.

Second, the calculated coefficient of variation for malaria incidence, which measures heterogeneity

between clusters, was 0.75 in the trial, higher than the estimate of 0.4 included in our sample size

calculations. Underestimating coefficient of variation can compromise trial power and reduce effect

size precision in cluster-randomised trials [33]. However, all outcomes measured in this trial (malaria

incidence and prevalence, vector parity and density) were greater in the intervention arm than in

the control, suggesting that we were unlikely to have rejected the null hypothesis in the trial, even if

it had been more sufficiently powered to detect a statistically significant reduction in malaria

incidence.

413 Conclusion

In a high transmission area in western Kenya, we found no evidence that ATSBs reduced malaria

incidence, prevalence, or vector parity and density, consistent with the results from the companion

trial in Zambia. Results from the partner trial Mali are expected soon, which may provide more

insight into the effectiveness of ATSBs in different transmission settings. Future work on ATSBs could

focus on steps in the causal pathway of impact (attraction, feeding, and mortality), the complex

interplay between sugar feeding and host seeking by malaria vectors, and density and coverage of

ATSBs in a variety of environmental and transmission settings. Further research on innovative

malaria control interventions is also needed to address outdoor biting and residual transmission, and

to help build the toolbox for integrated vector management.

Acknowledgments

We would like to thank the clinicians, monitors, community interviewers, human landing catch volunteers, the entomology laboratory and field teams, and community health promoters for their dedicated efforts in the collection of data and ensuring the smooth running of study activities. We are grateful to the social science team led by George Okello and Teresa Bange for helping us develop our community engagement strategy. We extend our appreciation to the Siaya County Ministry of Health for approving this study. We also thank the sub-county health management teams (Alego-Usonga and Rarieda) for facilitating community engagement and the health facility in-charges for their assistance with the cohort study and allowing their facilities to be used for storage of study supplies. Special thanks to Timothy Orwa the community liaison who was instrumental in community sensitization, Benta Kamire, Helen Wong, Sheila Nyarinda, and Maurice Ondeng for their instrumental roles in facilitating study activities, Dickens Riaga for ensuring the internal consistency of the trial and Dennis Omondi, the KEMRI/ CGHR Siaya laboratory manager for overseeing sample management. We are grateful to the Siaya County Commissioner and the national government staff who enabled us to conduct field activities without any issues. Lastly, we are grateful to all participants for their willingness to take part in this trial.

Author's contributions

EO, FtK, and AMS conceived the trial, with input from DM, JJ, MJD, and SK. EO, FtK, and AMS designed the study, developed the procedures, and drafted the protocol with contributions from DM, ML, JJ, CO, MC, MM, OT, WO, KO1, BS, SO, JK, and BP. CO, KO1, BS, SO, JK, and BP led field activities and data collection, under the oversight of SGS, FtK, AMS, and EO, with support from JS, JRG, JEG, and MJD. AK, DM, FA, and OT managed the data, and ML led the data analysis, with support from AK, DM and SGS. SO and JK led the entomology surveillance

447 and mosquito sample processing. KO2 coordinated the collection, processing, and storage of

448 blood samples. CO and SGS interpreted the data and drafted the manuscript, with input

449 from ML, DM, and AK. All authors reviewed the manuscript and approved it for publication.

450 CO, the corresponding author, had full access to all the data in the study and held final

451 responsibility for the decision to submit the manuscript for publication.

Declaration of interests

454 The authors declare that they have no competing interests.

Funding statement

457 This work was funded by Integrated Vector Control Consortium (IVCC), UK, through support from the

458 Bill & Melinda Gates Foundation (grant: INV-007509), the Swiss Agency for Development and

459 Cooperation (SDC) (grant: 81067480) and UK Aid (grant: 30041-105). The findings and conclusions

460 contained within are those of the authors and do not necessarily reflect positions or policies of the

461 Bill & Melinda Gates Foundation, SDC or UK Aid.

Data sharing statement

464 De-identified data are available from the corresponding author on reasonable request. Following

465 publication of forthcoming secondary analyses of trial data, the de-identified trial dataset will be

466 posted on a public repository.

Figure legends

Fig1: CONSORT flow diagram

Fig2: Map of study area: The study included 70 clusters, each consisting of a minimum of 100 households in the core area. Clusters were randomised 1:1 to intervention (ATSB) or control (standard care). A sub-set of 16 clusters were randomly selected for entomology surveillance.

Fig3: Study schema. Timeline of study activities between February 2022 to March 2024 Abbreviations – attractive targeted sugar bait (ATSB), continuous malaria indicator survey (cMIS), human landing catches (HLCs), ultraviolet light traps (UVLTs), cross-sectional surveys (CSS). Activities featured, include: four rounds of ATSB deployment and monitoring; enrolment and follow-up of three consecutive cohorts of children; two years of cMIS monitoring; seven cross-sectional mosquito collections using UVLTs; one year of entomology surveillance using HLCs and UVLTs for mosquito collections.

Supplemental files

S1. Malaria microscopy procedures

Table S1. Cohort study recruitment

Table S2. Serious adverse events & deaths

Table S3. Additional parity outcomes

References

1. Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature. 2015;526(7572):207-11. doi: 10.1038/nature15535. PubMed PMID: 26375008.

2. World Health Organization. World Malaria Report 2023. Geneva, Switzerland: World Health Organization, 2023.

3. Ranson H, Lissenden N. Insecticide Resistance in African Anopheles Mosquitoes: A Worsening Situation that Needs Urgent Action to Maintain Malaria Control. Trends Parasitol. 2016;32(3):187-96. doi: 10.1016/j.pt.2015.11.010. PubMed PMID: 26826784.

4. Abong'o B, Gimnig JE, Torr SJ, Longman B, Omoke D, Muchoki M, et al. Impact of indoor residual spraying with pirimiphos-methyl (Actellic 300CS) on entomological indicators of transmission and malaria case burden in Migori County, western Kenya. Scientific reports. 2020;10(1):4518. Epub 20200311. doi: 10.1038/s41598-020-61350-2. PubMed PMID: 32161302; PubMed Central PMCID: PMCPMC7066154.

5. Omondi S, Kosgei J, Musula G, Muchoki M, Abong'o B, Agumba S, et al. Late morning biting behaviour of Anopheles funestus is a risk factor for transmission in schools in Siaya, western Kenya. Malar J. 2023;22(1):366. Epub 2023/12/01. doi: 10.1186/s12936-023-04806-w. PubMed PMID: 38037026; PubMed Central PMCID: PMCPMC10691009.

6. Conrad MD, Asua V, Garg S, Giesbrecht D, Niaré K, Smith S, et al. Evolution of Partial Resistance to Artemisinins in Malaria Parasites in Uganda. N Engl J Med. 2023;389(8):722-32. Epub 2023/08/23. doi: 10.1056/NEJMoa2211803. PubMed PMID: 37611122; PubMed Central PMCID: PMCPMC10513755.

7. Alegana VA, Macharia PM, Muchiri S, Mumo E, Oyugi E, Kamau A, et al. Plasmodium falciparum parasite prevalence in East Africa: Updating data for malaria stratification. PLOS Glob Public Health. 2021;1(12):e0000014. Epub 2022/02/26. doi: 10.1371/journal.pgph.0000014. PubMed PMID: 35211700; PubMed Central PMCID: PMCPMC7612417.

8. Odero JI, Abong'o B, Moshi V, Ekodir S, Harvey SA, Ochomo E, et al. Early morning anopheline mosquito biting, a potential driver of malaria transmission in Busia County, western Kenya. Malar J. 2024;23(1):66. Epub 20240304. doi: 10.1186/s12936-024-04893-3. PubMed PMID: 38438933; PubMed Central PMCID: PMCPMC10910777.

9. Njoroge TM, Hamid-Adiamoh M, Duman-Scheel M. Maximizing the Potential of Attractive Targeted Sugar Baits (ATSBs) for Integrated Vector Management. Insects. 2023;14(7). Epub 20230628. doi: 10.3390/insects14070585. PubMed PMID: 37504591; PubMed Central PMCID: PMCPMC10380652.

10. Traore MM, Junnila A, Traore SF, Doumbia S, Revay EE, Kravchenko VD, et al. Large-scale field trial of attractive toxic sugar baits (ATSB) for the control of malaria vector mosquitoes in Mali,

West Africa. Malar J. 2020;19(1):72. Epub 20200214. doi: 10.1186/s12936-020-3132-0. PubMed
PMID: 32059671; PubMed Central PMCID: PMCPMC7023716.

11. Fraser KJ, Mwandigha L, Traore SF, Traore MM, Doumbia S, Junnila A, et al. Estimating the
potential impact of Attractive Targeted Sugar Baits (ATSBs) as a new vector control tool for
Plasmodium falciparum malaria. Malar J. 2021;20(1):151. Epub 20210317. doi: 10.1186/s12936-
021-03684-4. PubMed PMID: 33731111; PubMed Central PMCID: PMCPMC7968277.

12. Chanda J, Wagman J, Chanda B, Kaniki T, Ng'andu M, Muyabe R, et al. Feeding rates of malaria
vectors from a prototype attractive sugar bait station in Western Province, Zambia: results of an
entomological validation study. Malar J. 2023;22(1):70. Epub 20230301. doi: 10.1186/s12936-
023-04491-9. PubMed PMID: 36855105; PubMed Central PMCID: PMCPMC9974387.

13. Marshall JM, White MT, Ghani AC, Schlein Y, Muller GC, Beier JC. Quantifying the mosquito's
sweet tooth: modelling the effectiveness of attractive toxic sugar baits (ATSB) for malaria vector
control. Malar J. 2013;12:291. Epub 20130823. doi: 10.1186/1475-2875-12-291. PubMed PMID:
23968494; PubMed Central PMCID: PMCPMC3765557.

14. Attractive Targeted Sugar Bait Phase III Trial Group. Attractive targeted sugar bait phase III trials
in Kenya, Mali, and Zambia. Trials. 2022;23(1):640. Epub 2022/08/10. doi: 10.1186/s13063-022-
06555-8. PubMed PMID: 35945599; PubMed Central PMCID: PMCPMC9361277.

15. Yukich J, Eisele TP, terKuile F, Ashton R, Staedke S, Harris AF, et al. Master statistical analysis
plan: attractive targeted sugar bait phase III trials in Kenya, Mali, and Zambia. Trials.
2023;24(1):771. Epub 2023/11/30. doi: 10.1186/s13063-023-07762-7. PubMed PMID: 38031086;
PubMed Central PMCID: PMCPMC10685482.

16. Kamau A, Obiet K, Ogwang C, McDermott DP, Lesosky M, Janssen J, et al. Attractive targeted
sugar baits for malaria control in western Kenya (ATSB-Kenya): enrolment characteristics of
cohort children and households. Malar J. 2024;23(1):403. Epub 20241230. doi: 10.1186/s12936-
024-05234-0. PubMed PMID: 39736740; PubMed Central PMCID: PMCPMC11687092.

17. Odhiambo FO, Laserson KF, Sewe M, Hamel MJ, Feikin DR, Adazu K, et al. Profile: the KEMRI/CDC
Health and Demographic Surveillance System--Western Kenya. Int J Epidemiol. 2012;41(4):977-
87. doi: 10.1093/ije/dys108. PubMed PMID: 22933646.

18. Odero NA, Samuels AM, Odongo W, Abong'o B, Gimnig J, Otieno K, et al. Community-based
intermittent mass testing and treatment for malaria in an area of high transmission intensity,
western Kenya: development of study site infrastructure and lessons learned. Malar J.
2019;18(1):255. Epub 20190729. doi: 10.1186/s12936-019-2896-6. PubMed PMID: 31357997;
PubMed Central PMCID: PMCPMC6664589.

19. Samuels AM, Odero NA, Odongo W, Otieno K, Were V, Shi YP, et al. Impact of Community-Based
Mass Testing and Treatment on Malaria Infection Prevalence in a High-Transmission Area of
Western Kenya: A Cluster Randomized Controlled Trial. Clin Infect Dis. 2021;72(11):1927-35. doi:
10.1093/cid/ciaa471. PubMed PMID: 32324850; PubMed Central PMCID: PMCPMC9059430.

20. Bayoh MN, Mathias DK, Odiere MR, Mutuku FM, Kamau L, Gimnig JE, et al. Anopheles gambiae:
historical population decline associated with regional distribution of insecticide-treated bed nets
in western Nyanza Province, Kenya. Malaria journal. 2010;9:62. Epub 2010/03/02. doi:
10.1186/1475-2875-9-62. PubMed PMID: 20187956; PubMed Central PMCID: PMC2838909.

21. US President's Malaria Initiative. U.S. President's Malaria Initiative Kenya Malaria Operational
Plan, FY 2023. 2022.

22. Detinova TS. Age-grouping methods in Diptera of medical importance with special reference to
some vectors of malaria. Monogr Ser World Health Organ. 1962;47:13-191. PubMed PMID:
13885800.

23. Johnson PC, Barry SJ, Ferguson HM, Müller P. Power analysis for generalized linear mixed models
in ecology and evolution. Methods Ecol Evol. 2015;6(2):133-42. Epub 20141206. doi:
10.1111/2041-210x.12306. PubMed PMID: 25893088; PubMed Central PMCID:
PMCPMC4394709.

24. Wagman J, Chanda B, Chanda J, Saili K, Orange E, Mambo P, et al. Entomological effects of
attractive targeted sugar bait station deployment in Western Zambia: vector surveillance
findings from a two-arm cluster randomized phase III trial. Malar J. 2024;23(1):214. Epub
20240718. doi: 10.1186/s12936-024-05045-3. PubMed PMID: 39026236; PubMed Central
PMCID: PMCPMC11264679.

25. Ashton RA, Saili K, Chishya C, Banda Yikona H, Arnzen A, Orange E, et al. Efficacy of attractive
targeted sugar bait stations against malaria in Western Province Zambia: epidemiological
findings from a two-arm cluster randomized phase III trial. Malar J. 2024;23(1):343. Epub
20241115. doi: 10.1186/s12936-024-05175-8. PubMed PMID: 39548456; PubMed Central
PMCID: PMCPMC11566550.

26. Beier JC, Muller GC, Gu W, Arheart KL, Schlein Y. Attractive toxic sugar bait (ATSB) methods
decimate populations of Anopheles malaria vectors in arid environments regardless of the local
availability of favoured sugar-source blossoms. Malar J. 2012;11:31. Epub 20120201. doi:
10.1186/1475-2875-11-31. PubMed PMID: 22297155; PubMed Central PMCID:
PMCPMC3293779.

27. Yalla N, Polo B, McDermott DP, Kosgei J, Omondi S, Agumba S, et al. A comparison of the
attractiveness of flowering plant blossoms versus attractive targeted sugar baits (ATSBs) in
western Kenya. PLoS One. 2023;18(6):e0286679. Epub 20230606. doi:
10.1371/journal.pone.0286679. PubMed PMID: 37279239; PubMed Central PMCID:
PMCPMC10243617.

28. Diarra RA, Traore MM, Junnila A, Traore SF, Doumbia S, Revay EE, et al. Testing configurations of
attractive toxic sugar bait (ATSB) stations in Mali, West Africa, for improving the control of
malaria parasite transmission by vector mosquitoes and minimizing their effect on non-target
insects. Malar J. 2021;20(1):184. Epub 20210414. doi: 10.1186/s12936-021-03704-3. PubMed
PMID: 33853632; PubMed Central PMCID: PMCPMC8048058.

29. Omondi S, Kosgei J, Agumba S, Polo B, Yalla N, Moshi V, et al. Natural sugar feeding rates of
Anopheles mosquitoes collected by different methods in western Kenya. Scientific reports.
2022;12(1):20596. Epub 20221129. doi: 10.1038/s41598-022-25004-9. PubMed PMID:
36446923; PubMed Central PMCID: PMCPMC9709062.

30. Mwaanga G, Ford J, Yukich J, Chanda B, Ashton RA, Chanda J, et al. Residual bioefficacy of
attractive targeted sugar bait stations targeting malaria vectors during seasonal deployment in
Western Province of Zambia. Malaria Journal. 2024;23(1):169. doi: 10.1186/s12936-024-04990-
3.

31. Müller GC, Beier JC, Traore SF, Toure MB, Traore MM, Bah S, et al. Successful field trial of
attractive toxic sugar bait (ATSB) plant-spraying methods against malaria vectors in the
Anopheles gambiae complex in Mali, West Africa. Malaria Journal. 2010;9(1):210. doi:
10.1186/1475-2875-9-210.

32. Revay EE, Schlein Y, Tsabari O, Kravchenko V, Qualls W, De-Xue R, et al. Formulation of attractive
toxic sugar bait (ATSB) with safe EPA-exempt substance significantly diminishes the Anopheles
sergentii population in a desert oasis. Acta Trop. 2015;150:29-34. Epub 20150625. doi:
10.1016/j.actatropica.2015.06.018. PubMed PMID: 26119042; PubMed Central PMCID:
PMCPMC4720916.

33. Biggs J, Challenger JD, Hellewell J, Churcher TS, Cook J. A systematic review of sample size
estimation accuracy on power in malaria cluster randomised trials measuring epidemiological
outcomes. medRxiv. 2024:2024.04.08.24305485. doi: 10.1101/2024.04.08.24305485.

Figure

70 clusters randomised
32 in Alego Usonga
38 in Rarieda

35 clusters randomised to control

35 clusters randomised to intervention

Cohort 1 recruitment
887 on recruitment list
223 failed to contact
664 screened

Cohort 2 recruitment
665 recruitment list
77 failed to contact
588 screened

Cohort 3 recruitment
700 recruitment list
105 failed to contact
595 screened

Cohort 1 recruitment
892 on recruitment list
217 failed to contact
675 screened

Cohort 2 recruitment
665 recruitment list
84 failed to contact
581 screened

Cohort 3 recruitment
700 recruitment list
98 failed to contact
602 screened

Cohort 1 screening
168 excluded
115 not eligible
53 declined

Cohort 2 screening
103 excluded
71 not eligible
32 declined

Cohort 3 screening
111 excluded
87 not eligible
24 declined

Cohort 1 screening
171 excluded
118 not eligible
53 declined †

Cohort 2 screening
97 excluded
59 not eligible
38 declined †

Cohort 3 screening
93 excluded
73 not eligible
20 declined †

Cohort 1 enrolment
496 enrolled

Cohort 2 enrolment
485 enrolled

Cohort 3 enrolment
484 enrolled

Cohort 1 enrolment
504 enrolled

Cohort 2 enrolment
484 enrolled

Cohort 3 enrolment
509 enrolled

Cohort 1 follow-up
34 endpoint exclusions
23 clearance failure*
11 no person-time
after clearance

Cohort 2 follow-up
13 endpoint exclusions
10 clearance failure*
3 no person-time
after clearance

Cohort 3 follow-up
10 endpoint exclusions
6 clearance failure*
4 no person-time
after clearance

Cohort 1 follow-up
19 endpoint exclusions
16 clearance failure*
3 no person-time
after clearance

Cohort 2 follow-up
10 endpoint exclusions
8 clearance failure*
2 no person-time
after clearance

Cohort 3 follow-up
7 endpoint exclusions
3 clearance failure*
4 no person-time
after clearance

Cohort 1 analysis
462 in endpoint analysis

Cohort 2 analysis
472 in endpoint analysis

Cohort 3 analysis
474 in endpoint analysis

Cohort 1 analysis
485 in endpoint analysis

Cohort 2 analysis
474 in endpoint analysis

Cohort 3 analysis
502 in endpoint analysis

Figure

Study sub counties	
Intervention clusters	
Control clusters	
Entomology clusters	
Lakes	
Study Health Facilities	

Figure